Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
The Lancet Infectious Diseases·
- DOI
- 10.1016/s1473-3099(20)30847-1
- PMID
- 33333012
- PMCID
- PMC7833078
- OpenAlex
- W3112984291
- Study type
- Guideline
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The article provides a framework for more consistent case characterization and treatment decisions for COVID-19-associated pulmonary aspergillosis, including consideration of azole resistance. The supplied evidence does not quantify disease burden, treatment effects, or mortality.
Structured evidence summary
Research question
How should COVID-19-associated pulmonary aspergillosis be defined for research and clinical use, and what treatment approaches are recommended for its management?
Study design
Expert consensus statement endorsed by medical mycology societies, presented as a guideline rather than an empirical comparative study.
Population and setting
The guidance concerns patients with COVID-19 and suspected or diagnosed pulmonary aspergillosis. The supplied abstract does not specify a study sample, sites, or geographic setting.
Main findings
The statement proposes classifying cases as possible, probable, or proven according to specimen validity and diagnostic certainty. It recommends voriconazole or isavuconazole as initial treatment options, with liposomal amphotericin B when azole resistance is a concern.
Public-health relevance
The article provides a framework for more consistent case characterization and treatment decisions for COVID-19-associated pulmonary aspergillosis, including consideration of azole resistance. The supplied evidence does not quantify disease burden, treatment effects, or mortality.
Important limitations
The supplied abstract does not state formal limitations or provide the underlying evidence-review methods. This summary relies on a single-article abstract and bibliographic metadata; the original paper is required for decision-grade interpretation.
GIDS interpretation
The article is discoverable under COVID-19, diagnostics, antimicrobial resistance, treatment, and health policy topics. It offers contextual guidance for interpreting related literature but does not establish or confirm a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 13 auditable classifier relationships to diseases, places, topics, and study design.